Revolutionize Care with Pioneering Bispecific Antibody Therapy
Authors: Select Science | Last updated: December 2023
Overview
In this exclusive interview with Jiseon Kim, Senior Researcher at ProGen, we explore the groundbreaking research on the development of a novel antibody-based drug for the treatment of cancer and autoimmune diseases. Through the utilization of Neo Tri-ImmunoGlobulin (NTIG), a fusion protein platform designed to enable multi-targeting and long-term drug persistence, Kim’s team is revolutionizing the field of drug discovery and antibody-based medicine.
- Document type: Article
- Page count: 5
- Read time: 8 minutes
Key Takeaways
- Discover ProGen's NTIG technology for next-gen cancer and autoimmune disease treatments
- Learn how NTIG's multi-targeting approach surpasses conventional drug therapies
- Understand the challenges and importance of precise binding affinity in drug development
- Explore the role of the Octet® R8 BLI System in advancing antibody medicine
- Get to know how the mechanical pipette Tacta® facilitates and streamlines research effort and the Safe Cone Filter reduces the contamination of the pipette.
This Resource is Designed for:
- Oncologists
- Immunologists
- Researchers in the Field of Drug Discovery and Development
Applications Supported:
- Bispecific Antibody Therapy
- Drug Discovery and Development
- Cancer and Autoimmune Disease Treatment
- Biomedical Research
- Pipetting
- Mechanical Pipettes
Resource Preview
